The company has three business segments — Orthopaedics, MedSurg, and Neurotechnology & Spine.Strength in Stryker's flagship Mako Total Knee Platform, which enables surgeons to do pre-operative planning and precise surgeries, looks promising. The company is also adopting several cost-cutting measures, including restructuring plans. The company's prospects in 2024 seem promising on the back of strong customer demand for its existing products, as well as new launches. Stryker's recent strategic acquisitions also raise optimism about the stock.